



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Certificates of Correction Branch, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 2nd day of November, 2005.

By

*Kelley D. Surprenant*  
(Signature of person mailing)

Kelley D. Surprenant

(Typed or printed name of person)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Cavaleri et al.

Pat. No. 6,900,175 B2

Appln. No.: 10/714,261

Filed 14 November 2003

For: Method of Administering Dalbavancin  
for Treatment of Bacterial Infections

Group Art Unit: 1623

Examiner: E. Peselev

**REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR § 1.323**

Certificates of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

Dear Sir:

The attached Certificate of Correction on Form PTO/SB/44 is being submitted to correct a mistake in US Patent No. 6,900,175. Specifically, the structure drawing at columns 7-8 of the patent requires minor correction such that the substitution at C15, *i.e.*, the substitution pattern on the phenyl ring in the lower right portion of the molecule is correct, as shown in the attached. The scope of the claims is unchanged and no new matter is presented.

**Certificate  
NOV 14 2005  
of Correction**

11/08/2005 YPOLITE1 00000047 161445 6900175

01 FC:1811 100.00 DA

The Commissioner is hereby authorized to charge the appropriate fee under Rule 1.20(a) of \$100.00 and to charge any deficiency or credit any overpayment to Deposit Account No. 16-1445.

Respectfully Submitted:

Date: 2 Nov 05

  
Frank W. Forman  
Attorney for Patentees  
Registration No. 42,547


Pfizer Inc. - Patent Department  
Eastern Point Road MS 8260-1611  
Groton, Connecticut 06340  
(860) 715-5669  
Frank.W.Forman@Pfizer.com

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION


PATENT NO. : 6,900,175 B2  
DATED : May 31, 2005  
INVENTOR(S) : Cavaleri, M. et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Columns 7 and 8, delete the following chemical structure



and insert the following chemical structure



## MAILING ADDRESS OF SENDER:

Frank W. Forman  
Pfizer Inc. - Patent Department  
Eastern Point Road MS 8260-1611  
Groton, CT 06340

PATENT NO. 6,900,175

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer,